TMC Life Sciences Bhd
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. The company operates Thomson Hospital Kota Damansara hospital located in prime alcove of Kota Damansara. It is involved in providing multi-disciplinary tertiary care, traditional and complementary, obstetrics and gynaecology, fertility services; operating fertility centres and women clinics; propert… Read more
TMC Life Sciences Bhd (0101) - Net Assets
Latest net assets as of November 2025: RM860.77 Million MYR
Based on the latest financial reports, TMC Life Sciences Bhd (0101) has net assets worth RM860.77 Million MYR as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM1.12 Billion) and total liabilities (RM258.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM860.77 Million |
| % of Total Assets | 76.91% |
| Annual Growth Rate | 16.23% |
| 5-Year Change | 8.03% |
| 10-Year Change | 34.49% |
| Growth Volatility | 41.86 |
TMC Life Sciences Bhd - Net Assets Trend (2006–2025)
This chart illustrates how TMC Life Sciences Bhd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TMC Life Sciences Bhd (2006–2025)
The table below shows the annual net assets of TMC Life Sciences Bhd from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | RM853.04 Million | -3.94% |
| 2024-08-31 | RM888.03 Million | +3.03% |
| 2023-08-31 | RM861.96 Million | +4.18% |
| 2022-08-31 | RM827.39 Million | +4.78% |
| 2021-08-31 | RM789.62 Million | +2.27% |
| 2020-08-31 | RM772.12 Million | +1.30% |
| 2019-08-31 | RM762.24 Million | +2.97% |
| 2018-08-31 | RM740.24 Million | +3.61% |
| 2017-08-31 | RM714.42 Million | +12.64% |
| 2016-08-31 | RM634.26 Million | +110.22% |
| 2015-08-31 | RM301.71 Million | +122.84% |
| 2014-08-31 | RM135.39 Million | +3.11% |
| 2013-08-31 | RM131.31 Million | +9.25% |
| 2012-08-31 | RM120.19 Million | +81.99% |
| 2011-08-31 | RM66.04 Million | -36.21% |
| 2009-08-31 | RM103.54 Million | -9.19% |
| 2008-08-31 | RM114.02 Million | +51.35% |
| 2007-08-31 | RM75.33 Million | +53.85% |
| 2006-08-31 | RM48.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TMC Life Sciences Bhd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 941.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RM227.06 Million | 26.62% |
| Common Stock | RM625.99 Million | 73.38% |
| Total Equity | RM853.04 Million | 100.00% |
TMC Life Sciences Bhd Competitors by Market Cap
The table below lists competitors of TMC Life Sciences Bhd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Doral Group Renewable Energy Resources Ltd
TA:DORL
|
$32.97 Million |
|
Sarla Performance Fibers Limited
NSE:SARLAPOLY
|
$32.98 Million |
|
Virgin Group Acquisition Corp II
NYSE:GROV
|
$32.98 Million |
|
Perdana Karya Perkasa Tbk
JK:PKPK
|
$32.99 Million |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
$32.95 Million |
|
Ottawa Savings Bancorp Inc
OTCQX:OTTW
|
$32.94 Million |
|
REC Silicon ASA
PINK:RNWEF
|
$32.94 Million |
|
Myungmoon Phar
KO:017180
|
$32.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TMC Life Sciences Bhd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 888,034,000 to 853,043,000, a change of -34,991,000 (-3.9%).
- Net income of 3,606,000 contributed positively to equity growth.
- Dividend payments of 38,616,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,316,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM3.61 Million | +0.42% |
| Dividends Paid | RM38.62 Million | -4.53% |
| Other Comprehensive Income | RM-1.32 Million | -0.15% |
| Other Changes | RM1.33 Million | +0.16% |
| Total Change | RM- | -3.94% |
Book Value vs Market Value Analysis
This analysis compares TMC Life Sciences Bhd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.87x to 1.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-08-31 | RM0.27 | RM0.50 | x |
| 2007-08-31 | RM0.40 | RM0.50 | x |
| 2008-08-31 | RM0.20 | RM0.50 | x |
| 2009-08-31 | RM0.16 | RM0.50 | x |
| 2011-08-31 | RM0.11 | RM0.50 | x |
| 2012-08-31 | RM0.14 | RM0.50 | x |
| 2013-08-31 | RM0.11 | RM0.50 | x |
| 2014-08-31 | RM0.11 | RM0.50 | x |
| 2015-08-31 | RM0.31 | RM0.50 | x |
| 2016-08-31 | RM0.34 | RM0.50 | x |
| 2017-08-31 | RM0.38 | RM0.50 | x |
| 2018-08-31 | RM0.41 | RM0.50 | x |
| 2019-08-31 | RM0.44 | RM0.50 | x |
| 2020-08-31 | RM0.44 | RM0.50 | x |
| 2021-08-31 | RM0.45 | RM0.50 | x |
| 2022-08-31 | RM0.47 | RM0.50 | x |
| 2023-08-31 | RM0.49 | RM0.50 | x |
| 2024-08-31 | RM0.51 | RM0.50 | x |
| 2025-08-31 | RM0.49 | RM0.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TMC Life Sciences Bhd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.04%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.33x
- Recent ROE (0.42%) is below the historical average (0.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 18.72% | 36.81% | 0.41x | 1.24x | RM4.27 Million |
| 2007 | 12.38% | 29.85% | 0.33x | 1.25x | RM1.80 Million |
| 2008 | 3.14% | 9.21% | 0.23x | 1.49x | RM-7.83 Million |
| 2009 | -8.51% | -18.65% | 0.27x | 1.68x | RM-19.15 Million |
| 2011 | -53.02% | -43.44% | 0.55x | 2.21x | RM-41.62 Million |
| 2012 | -5.34% | -10.36% | 0.40x | 1.28x | RM-18.44 Million |
| 2013 | 8.44% | 15.34% | 0.46x | 1.19x | RM-2.05 Million |
| 2014 | 4.77% | 7.47% | 0.53x | 1.22x | RM-7.08 Million |
| 2015 | 3.29% | 9.62% | 0.30x | 1.13x | RM-20.25 Million |
| 2016 | 2.35% | 11.66% | 0.18x | 1.10x | RM-48.53 Million |
| 2017 | 3.64% | 17.16% | 0.20x | 1.08x | RM-45.41 Million |
| 2018 | 3.75% | 16.44% | 0.21x | 1.08x | RM-46.23 Million |
| 2019 | 2.74% | 10.73% | 0.23x | 1.11x | RM-55.30 Million |
| 2020 | 2.06% | 8.65% | 0.19x | 1.23x | RM-61.28 Million |
| 2021 | 2.57% | 10.08% | 0.19x | 1.34x | RM-58.71 Million |
| 2022 | 5.00% | 16.98% | 0.22x | 1.37x | RM-41.35 Million |
| 2023 | 4.55% | 12.60% | 0.26x | 1.37x | RM-46.94 Million |
| 2024 | 4.58% | 11.73% | 0.29x | 1.34x | RM-48.16 Million |
| 2025 | 0.42% | 1.04% | 0.31x | 1.33x | RM-81.70 Million |
Industry Comparison
This section compares TMC Life Sciences Bhd's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $3,605,455,318
- Average return on equity (ROE) among peers: 32.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TMC Life Sciences Bhd (0101) | RM860.77 Million | 18.72% | 0.30x | $32.96 Million |
| Optimax Holdings Sdn Bhd (0222) | $20.79 Million | 21.38% | 1.70x | $16.67 Million |
| Cengild Medical Berhad (0243) | $9.79 Million | 40.37% | 3.81x | $12.91 Million |
| DC HEALTHCARE HOLDINGS BERHAD (0283) | $4.75 Million | 39.98% | 2.55x | $5.43 Million |
| ALPHA (0303) | $54.55 Million | 97.60% | 0.76x | $71.95 Million |
| Metro Healthcare Berhad (0329) | $34.34 Million | 27.49% | 0.46x | $4.19 Million |
| PMCK Berhad (0363) | $81.09 Million | 13.23% | 0.33x | $422.79 |
| IHH Healthcare Bhd (5225) | $25.90 Billion | 3.74% | 0.50x | $6.43 Billion |
| KPJ Healthcare Bhd (5878) | $2.74 Billion | 12.92% | 1.70x | $2.09 Billion |